Posted by Michael Wonder on 02 Jun 2022
Fast track designation granted to MTX110 development for the treatment of recurrent glioblastoma
1 June 2022 - Midatech Pharma is pleased to announce that upon submitting an application to the U.S. FDA, its development programme of MTX110 for the treatment of recurrent glioblastoma has been granted fast track designation by the agency.
MTX110, a water soluble formulation of panobinostat, will soon start recruitment into a company sponsored Phase I study in patients with recurrent recurrent glioblastoma.
